AmerisourceBergen Announces Organizational Changes

VALLEY FORGE, Pa.--(Business Wire)--
AmerisourceBergen Corporation (NYSE: ABC) today announced organizational
changes, effective September 1, 2009, to better position the Company to continue
to achieve its long-term financial goals.

Steven H. Collis will become Executive Vice President AmerisourceBergen and
President of AmerisourceBergen Drug Corporation (ABDC), the Company`s largest
subsidiary. Collis was previously Executive Vice President and President of
AmerisourceBergen Specialty Group (ABSG). He led ABSG from a start-up company in
1994 to the approximately $15 billion subsidiary it is today. In his new role,
he will lead the ABDC organization. He continues to report directly to R. David
Yost, President and Chief Executive Officer of AmerisourceBergen Corporation.

"ABDC has been very successful since we began running it with Executive Vice
President and Chief Financial Officer Mike DiCandilo leading operations and me
leading sales and marketing," said Yost. "To drive future performance, we are
consolidating those functions under one leader, and I am very pleased that Steve
Collis will be applying his substantial management talent to lead ABDC. At the
same time, Mike DiCandilo will continue his corporate role with ABDC in finance,
supply chain management and our very important Business Transformation ERP
project. The result will be an even more focused organization."

Michael D. DiCandilo, continues as Executive Vice President and Chief Financial
Officer of AmerisourceBergen, with on-going responsibility for all corporate
financial operations, supply chain management, AmerisourceBergen Packaging
Group, and information technology, including the Company`s Business
Transformation ERP project. He continues to report directly to Yost.

Michael A. Mullen will lead ABSG as Chief Operating Officer, AmerisourceBergen
Specialty Group, also reporting directly to Yost. Prior to his new assignment,
Mullen, who has been with ABSG for six years, was President of Distribution
Services at ABSG, previously served as the chief financial officer for the
subsidiary, and has been a key force behind the long-running success of ABSG.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both pharmaceutical manufacturers and healthcare providers in the
pharmaceutical supply channel, the Company provides drug distribution and
related services designed to reduce costs and improve patient outcomes.
AmerisourceBergen's service solutions range from pharmacy automation and
pharmaceutical packaging to reimbursement and pharmaceutical consulting
services. With more than $70 billion in annual revenue, AmerisourceBergen is
headquartered in Valley Forge, PA, and employs approximately 10,000 people.
AmerisourceBergen is ranked #26 on the Fortune 500 list. For more information,
go to www.amerisourcebergen.com.

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements about AmerisourceBergen`s
future business and financial performance, estimates and prospects. These
statements are based on management`s current expectations and are subject to
uncertainty and changes in circumstances. Actual results may vary materially
from the expectations contained in the forward-looking statements. The following
factors, among others, could cause actual results to differ materially from
those described in any forward-looking statements: changes in pharmaceutical
market growth rates; the loss of one or more key customer or supplier
relationships; changes in customer mix; customer delinquencies, defaults or
insolvencies; supplier defaults or insolvencies; changes in pharmaceutical
manufacturers` pricing and distribution policies or practices; adverse
resolution of any contract or other dispute with customers or suppliers; federal
and state government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled substances;
changes in U.S. legislation or regulatory action affecting pharmaceutical
product pricing or reimbursement policies, including under Medicaid and
Medicare; changes in regulatory or clinical medical guidelines and/or labeling
for the pharmaceuticals we distribute, including certain anemia products; price
inflation in branded pharmaceuticals and price deflation in generics;
significant breakdown or interruption of our information technology systems; our
inability to implement an enterprise resource planning (ERP) system to handle
business and financial processes within AmerisourceBergen Drug Corporation`s
operations and our corporate functions without operating problems and/or cost
overruns; success of integration, restructuring or systems initiatives; interest
rate and foreign currency exchange rate fluctuations; economic, business,
competitive and/or regulatory developments in Canada, the United Kingdom and
elsewhere outside of the United States, including potential changes in Canadian
provincial legislation or regulatory action to lower pharmaceutical product
pricing and service fees; the impact of divestitures or the acquisition of
businesses that do not perform as we expect or that are difficult for us to
integrate or control; our inability to successfully complete any other
transaction that we may wish to pursue from time to time; changes in tax
legislation or adverse resolution of challenges to our tax positions; increased
costs of maintaining, or reductions in our ability to maintain, adequate
liquidity and financing sources; continued volatility, and further deterioration
of the capital and credit markets; and other economic, business, competitive,
legal, tax, regulatory and/or operational factors affecting our business
generally.Our most recent annual report on Form 10-K, quarterly reports on Forms
10-Q and current reports 8-K (which we may revise or supplement in future
reports filed to the SEC) provide additional information about these risks,
uncertainties and other matters. We do not undertake to update our
forward-looking statements.

AmerisourceBergen Corporation
Michael N. Kilpatric
610-727-7118
mkilpatric@amerisourcebergen.com

Copyright Business Wire 2009